126 related articles for article (PubMed ID: 30324544)
1. Mesothelin as a target for cervical cancer therapy.
Jöhrens K; Lazzerini L; Barinoff J; Sehouli J; Cichon G
Arch Gynecol Obstet; 2019 Jan; 299(1):211-216. PubMed ID: 30324544
[TBL] [Abstract][Full Text] [Related]
2. Favorable therapeutic response after anti-Mesothelin antibody-drug conjugate treatment requires high expression of Mesothelin in tumor cells.
Lazzerini L; Jöhrens K; Sehouli J; Cichon G
Arch Gynecol Obstet; 2020 Nov; 302(5):1255-1262. PubMed ID: 32815024
[TBL] [Abstract][Full Text] [Related]
3. First-in-Human, Multicenter, Phase I Dose-Escalation and Expansion Study of Anti-Mesothelin Antibody-Drug Conjugate Anetumab Ravtansine in Advanced or Metastatic Solid Tumors.
Hassan R; Blumenschein GR; Moore KN; Santin AD; Kindler HL; Nemunaitis JJ; Seward SM; Thomas A; Kim SK; Rajagopalan P; Walter AO; Laurent D; Childs BH; Sarapa N; Elbi C; Bendell JC
J Clin Oncol; 2020 Jun; 38(16):1824-1835. PubMed ID: 32213105
[TBL] [Abstract][Full Text] [Related]
4. Mesothelin Immunotherapy for Cancer: Ready for Prime Time?
Hassan R; Thomas A; Alewine C; Le DT; Jaffee EM; Pastan I
J Clin Oncol; 2016 Dec; 34(34):4171-4179. PubMed ID: 27863199
[TBL] [Abstract][Full Text] [Related]
5. Anetumab ravtansine: a novel mesothelin-targeting antibody-drug conjugate cures tumors with heterogeneous target expression favored by bystander effect.
Golfier S; Kopitz C; Kahnert A; Heisler I; Schatz CA; Stelte-Ludwig B; Mayer-Bartschmid A; Unterschemmann K; Bruder S; Linden L; Harrenga A; Hauff P; Scholle FD; Müller-Tiemann B; Kreft B; Ziegelbauer K
Mol Cancer Ther; 2014 Jun; 13(6):1537-48. PubMed ID: 24714131
[TBL] [Abstract][Full Text] [Related]
6. Safety and activity of anti-mesothelin antibody-drug conjugate anetumab ravtansine in combination with pegylated-liposomal doxorubicin in platinum-resistant ovarian cancer: multicenter, phase Ib dose escalation and expansion study.
Santin AD; Vergote I; González-Martín A; Moore K; Oaknin A; Romero I; Diab S; Copeland LJ; Monk BJ; Coleman RL; Herzog TJ; Siegel J; Kasten L; Schlicker A; Schulz A; Köchert K; Walter AO; Childs BH; Elbi C; Bulat I
Int J Gynecol Cancer; 2023 Apr; 33(4):562-570. PubMed ID: 36564099
[TBL] [Abstract][Full Text] [Related]
7. Exploiting mesothelin in thymic carcinoma as a drug delivery target for anetumab ravtansine.
Chen V; Umemura S; Han Y; Raman R; Tucker R; Chahine J; Kim IK; Schatz C; Zitzmann-Kolbe S; Sommer A; Onda M; Lee T; He Y; Giaccone G
Br J Cancer; 2022 Mar; 126(5):754-763. PubMed ID: 34876673
[TBL] [Abstract][Full Text] [Related]
8. Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.
Quanz M; Hagemann UB; Zitzmann-Kolbe S; Stelte-Ludwig B; Golfier S; Elbi C; Mumberg D; Ziegelbauer K; Schatz CA
Oncotarget; 2018 Sep; 9(75):34103-34121. PubMed ID: 30344925
[TBL] [Abstract][Full Text] [Related]
9. Anti-glypican-1 antibody-drug conjugate exhibits potent preclinical antitumor activity against glypican-1 positive uterine cervical cancer.
Matsuzaki S; Serada S; Hiramatsu K; Nojima S; Matsuzaki S; Ueda Y; Ohkawara T; Mabuchi S; Fujimoto M; Morii E; Yoshino K; Kimura T; Naka T
Int J Cancer; 2018 Mar; 142(5):1056-1066. PubMed ID: 29055044
[TBL] [Abstract][Full Text] [Related]
10. Novel mesothelin antibody-drug conjugates: current evidence and future role in the treatment of ovarian cancer.
Mauricio D; Harold J; Tymon-Rosario JR; Zeybek B; Santin AD
Expert Opin Biol Ther; 2021 Aug; 21(8):1087-1096. PubMed ID: 33356644
[No Abstract] [Full Text] [Related]
11. Targeting Mesothelin in Solid Tumours: Anti-mesothelin Antibody and Drug Conjugates.
Chu Q
Curr Oncol Rep; 2023 Apr; 25(4):309-323. PubMed ID: 36763234
[TBL] [Abstract][Full Text] [Related]
12. Mesothelin: a new target for immunotherapy.
Hassan R; Bera T; Pastan I
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3937-42. PubMed ID: 15217923
[TBL] [Abstract][Full Text] [Related]
13. Humoral immune response to mesothelin in mesothelioma and ovarian cancer patients.
Ho M; Hassan R; Zhang J; Wang QC; Onda M; Bera T; Pastan I
Clin Cancer Res; 2005 May; 11(10):3814-20. PubMed ID: 15897581
[TBL] [Abstract][Full Text] [Related]
14. Mesothelin-Targeted Thorium-227 Conjugate (MSLN-TTC): Preclinical Evaluation of a New Targeted Alpha Therapy for Mesothelin-Positive Cancers.
Hagemann UB; Ellingsen C; Schuhmacher J; Kristian A; Mobergslien A; Cruciani V; Wickstroem K; Schatz CA; Kneip C; Golfier S; Smeets R; Uran S; Hennekes H; Karlsson J; Bjerke RM; Ryan OB; Mumberg D; Ziegelbauer K; Cuthbertson AS
Clin Cancer Res; 2019 Aug; 25(15):4723-4734. PubMed ID: 31064781
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Anti-mesothelin Immunotoxin RG7787 plus Nab-Paclitaxel against Mesothelioma Patient-Derived Xenografts and Mesothelin as a Biomarker of Tumor Response.
Zhang J; Khanna S; Jiang Q; Alewine C; Miettinen M; Pastan I; Hassan R
Clin Cancer Res; 2017 Mar; 23(6):1564-1574. PubMed ID: 27635089
[No Abstract] [Full Text] [Related]
16. Discovery of mesothelin and exploiting it as a target for immunotherapy.
Pastan I; Hassan R
Cancer Res; 2014 Jun; 74(11):2907-12. PubMed ID: 24824231
[TBL] [Abstract][Full Text] [Related]
17. Antibody-drug conjugates in gynecologic malignancies.
Lee EK; Liu JF
Gynecol Oncol; 2019 Jun; 153(3):694-702. PubMed ID: 30929824
[TBL] [Abstract][Full Text] [Related]
18. Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts.
ter Weele EJ; Terwisscha van Scheltinga AG; Kosterink JG; Pot L; Vedelaar SR; Lamberts LE; Williams SP; Lub-de Hooge MN; de Vries EG
Oncotarget; 2015 Dec; 6(39):42081-90. PubMed ID: 26536664
[TBL] [Abstract][Full Text] [Related]
19. ImmunoPET with Anti-Mesothelin Antibody in Patients with Pancreatic and Ovarian Cancer before Anti-Mesothelin Antibody-Drug Conjugate Treatment.
Lamberts LE; Menke-van der Houven van Oordt CW; ter Weele EJ; Bensch F; Smeenk MM; Voortman J; Hoekstra OS; Williams SP; Fine BM; Maslyar D; de Jong JR; Gietema JA; Schröder CP; Bongaerts AH; Lub-de Hooge MN; Verheul HM; Sanabria Bohorquez SM; Glaudemans AW; de Vries EG
Clin Cancer Res; 2016 Apr; 22(7):1642-52. PubMed ID: 26589435
[TBL] [Abstract][Full Text] [Related]
20. Application of mesothelin immunostaining in tumor diagnosis.
Ordóñez NG
Am J Surg Pathol; 2003 Nov; 27(11):1418-28. PubMed ID: 14576474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
